Overview

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

Status:
Completed
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.
Phase:
Phase 3
Details
Lead Sponsor:
Gage Development Company, LLC
Treatments:
Diclofenac